Criteria
Not Satisfactory
The story quoted another news source quoting the researcher, who claimed “that HIFU may also be cheaper than other standard treatments, noting that the cost of the MRI and mapping was an estimated $2,400, plus about $1,600 for HIFU; in comparison, removing the prostate costs about $7,100. Fewer side effects would also lower other health care costs, he said.”
But that quote from the researcher may have been an incomplete assessment of costs.
It’s unknown if cancers are more likely to recur following HIFU. If they were, then ultimate costs would be higher. In fact, the Lancet article noted that 4 men required retreatment within one year. Additionally, 39 of 41 men had repeat MRI/biopsy after 6 months. While that may have been just part of the research protocol, the extent to which repeat MRI/biopsy are part of clinical practice would also contribute to costs.
Not Satisfactory
We’re told that “Overall, about 95% of the men were cancer-free after a full year following the trial.” But, again, that may have been an incomplete picture.
The Lancet article indicates that this includes 4 men who required retreatment. “Cancer-free” is based on MRI results. Most men were also biopsied after 6 months to determine whether there was microscopic evidence of cancer and 9 of 39 did have evidence.
Not Satisfactory
The story stated that “None of the patients reported urinary incontinence a year after treatment, and only 1 in 10 suffered from poor erections.” Again, this was not the whole story. 17% of men developed urinary tract infections after the procedure and men required catheters for an average of 8 days.
Not Satisfactory
The story states that:
While the initial results were promising, they need to be replicated; HIFU also needs to be studied long-term and compared with other therapies. If the technology holds up, it could also work for other cell-based cancers like breast, thyroid, pancreas and liver, Ahmed said.
But, given that this was a proof of concept study in just 41 men, the emphasis should have been greater that this was very preliminary data. It was also an uncontrolled trial (no control group for comparison), yet the story allowed the researcher to get away with making claims about a better chance of “the perfect outcome” from this approach.
Then, letting him get away with this comment at this early stage was a bit over the top: “If the technology holds up, it could also work for other cell-based cancers like breast, thyroid, pancreas and liver.”
The Lancet article appropriately noted that one-year followup is far too short to fully evaluate cancer outcomes.
Satisfactory
No disease mongering.
Not Satisfactory
No independent sources were quoted – only the lead researcher.
Not Satisfactory
As noted in the “Evidence” criterion above, we feel the story allowed the researcher to get away with making comparative claims of superiority after a very preliminary study in just 41 men.
Among the other therapies to be mentioned would be active surveillance (deferring any active treatment until/unless there is evidence of cancer progression), which is an appropriate strategy for men with low-risk cancers (27% of the study group according to the Lancet article).
Not Satisfactory
The story was about a British study. There was no mention of the availability of HIFU in the US.
Not Satisfactory
The story made no reference to any past research on HIFU for prostate cancer. This isn’t the first research in this area – yet the story may suggest that to readers.
Not Applicable
The story appears to be based on someone else’s story – Bloomberg’s.
The intent of this criterion is to promote independent vetting of claims.
We’re not sure that happened any more with this approach than it would with copying from a news release.
We’ll rule it Not Applicable because we certainly can’t give this a Satisfactory score.
Total Score: 1 of 9 Satisfactory
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like